Earlier this week BMS submitted a dossier to the Scottish Medicines Consortium as part of the assessment of Dasatinib/Sprycel. The SMC will carry out an evaluation and decide whether or not to approve funding of
the drug for use within the NHS in Scotland.
In the same way as NICE does for England the SMC process allows for patient group input.
If you are based in Scotland you may be interested in having further information on this process, which includes guidance for patient groups and a submission template. It is available on the SMC website at
http://www.scottishmedicines.org.uk/.
best wishes,
sandy ;o)